The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Overall survival (OS) benefit with sipuleucel-T by baseline PSA: An exploratory analysis from the phase III IMPACT trial.
Gerald Chodak
Consultant or Advisory Role - Dendreon
Stock Ownership - Dendreon
Honoraria - Dendreon
Research Funding - Dendreon
Paul F. Schellhammer
Honoraria - Dendreon
James Boyd Whitmore
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Robert Brownell Sims
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Philip W. Kantoff
Consultant or Advisory Role - Dendreon